A novel formulation of selegiline for the treatment of Parkinson's disease

Neurology. 2004 Oct 12;63(7 Suppl 2):S2-6. doi: 10.1212/wnl.63.7_suppl_2.s2.
No abstract available

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Absorption
  • Administration, Oral
  • Antiparkinson Agents / administration & dosage*
  • Antiparkinson Agents / pharmacokinetics
  • Antiparkinson Agents / pharmacology
  • Biotransformation
  • Forecasting
  • Freeze Drying
  • Humans
  • Monoamine Oxidase Inhibitors / administration & dosage*
  • Monoamine Oxidase Inhibitors / pharmacokinetics
  • Monoamine Oxidase Inhibitors / pharmacology
  • Mouth Mucosa / metabolism
  • Parkinson Disease / drug therapy*
  • Randomized Controlled Trials as Topic
  • Selegiline / administration & dosage*
  • Selegiline / pharmacokinetics
  • Selegiline / pharmacology
  • Solubility
  • Tablets
  • Treatment Outcome

Substances

  • Antiparkinson Agents
  • Monoamine Oxidase Inhibitors
  • Tablets
  • Selegiline